Amar Sawhney, Ph.D.
President, Chief Executive Officer and Chairman of the Board of Directors
Amarpreet Sawhney, Ph.D., has served as President, Chief Executive Officer and a member of our Board since co-founding the Company in 2006, and he was elected as Chairman of the Board in June 2014. Dr. Sawhney served as CEO of Augmenix, an affiliate of Ocular Therapeutix, from 2008 until April 2014. In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health in 2014. Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.
Chief Operating Officer
Jim Fortune has more than 25 years of senior operating experience in both public and private companies within the healthcare sector. He joined Ocular Therapeutix in 2008, also serving as Chief Operating Officer of Augmenix from 2008 until April 2014 and as COO of AccessClosure from 2008 to 2010. Previously, Mr. Fortune served in COO positions at Intrinsic Therapeutics and, prior to this, at Confluent Surgical. He also had a 17-year career in management roles of increasing responsibility within the orthopedic and neurosurgical divisions of Johnson & Johnson. Mr. Fortune received a B.S. degree in mechanical engineering from Rensselaer Polytechnic Institute.
Chief Commercial Officer
Andy Hurley joined Ocular Therapeutix in late 2016 and brings to the company over 20 years of commercial leadership experience across sales, marketing, commercial operations, and managed care functions within the pharmaceutical industry. Prior to joining Ocular Therapeutix, Mr. Hurley served as Vice President, Sales and Marketing at Dyax Corporation. Prior to Dyax, Mr. Hurley was a Principal at Capgemini Consulting, a top 5 global, management consulting firm where he was responsible for leading the sales and marketing effectiveness practice within the life sciences group. Before joining Capgemini, Mr. Hurley held several senior level positions within Sunovion Pharmaceuticals, including Vice President of Marketing and Vice President of Commercial Operations. At Sunovion, he was responsible for leading all marketing activities for the asthma franchise and also had the opportunity to lead 11 functions within the Commercial Operations department. Earlier in his career, Mr. Hurley held sales leadership and commercial operations roles at Forest Pharmaceuticals and NitroMed. Mr. Hurley earned a B.S. degree in Consumer Studies at the University of Vermont and pursued graduate-level coursework in Marketing and Finance at Bentley University.
Peter Jarrett, Ph.D.
Chief Scientific Officer
Peter Jarrett, Ph.D., has more than 30 years of R&D experience, ranging from discovery to commercialization. Dr. Jarrett joined Ocular Therapeutix in 2007. Previously, he was Vice President of R&D at Focal, subsequently being named VP of Biomaterials R&D at Genzyme upon the latter company’s acquisition of Focal. Dr. Jarrett began his career in Corporate R&D of American Cyanamid, later moving to the Davis and Geck division. At Cyanamid, Focal, Genzyme and Ocular, Dr. Jarrett developed bioresorbable polymers for medical devices and drug delivery systems, resulting in numerous patents and publications. Dr. Jarrett holds a B.A. degree in chemistry from Connecticut College and a Ph.D. degree in polymer science from the University of Connecticut Institute of Materials Science.
Chief Financial Officer
Brad Smith brings over 20 years of experience in the life sciences, serving as Chief Financial Officer for several public and private emerging growth biotechnology, medical device and healthcare information technology companies. Prior to joining Ocular Therapeutix in March 2014, Mr. Smith served as CFO at OmniGuide Surgical, and previously as CFO at NeuroMetrix. He also held CFO and senior financial roles at various other healthcare companies, including Synarc, Inc., Focal, Inc., PatientKeeper, and CytoTherapeutics. Mr. Smith has been responsible for over $250 million in equity financing and has taken two companies public. Mr. Smith holds a B.S. degree in biology from Tufts University and an M.B.A. degree from the Whittemore School at the University of New Hampshire.
Jonathan Talamo, M.D.
Chief Medical Officer
Jonathan Talamo, M.D., joined Ocular Therapeutix in 2016, bringing more than 25 years of experience as an ophthalmologist, innovator, and clinical investigator. During his career, Dr. Talamo has advised numerous early to late-stage ophthalmology companies and served as an investigator for clinical trials leading to FDA approvals of PRK, LASIK and refractive cataract surgery technologies. He was also Associate Professor of Ophthalmology at Harvard Medical School and served as Director of the Massachusetts Eye and Ear Infirmary (MEEI) Waltham, a Harvard-affiliated teaching hospital. Dr. Talamo received his M.D. degree from The Johns Hopkins University School of Medicine and completed an ophthalmology residency at the Wilmer Ophthalmological Institute at Johns Hopkins. He also completed a clinical fellowship in cornea and external disease at Massachusetts Eye and Ear Infirmary.
Eric Ankerud, J.D.
Executive Vice President, Regulatory, Quality, and Compliance
Eric Ankerud has more than 25 years of product approval experience covering a wide range of pharmaceuticals, medical devices, and biologics. He joined Ocular Therapeutix in 2007, also serving as Executive Vice President, Clinical, Regulatory and Quality at a sister company Augmenix from 2008 until April 2014. Previously, Mr. Ankerud was the Vice President, Clinical, Regulatory and Quality of Confluent Surgical, Inc., and prior to this, held senior executive positions at Boston Scientific Corporation, Summit Technology, Inc., and Bausch + Lomb. He has also held senior management roles within C.R. Bard and its Surgical Products Group. Mr. Ankerud received a B.A. degree with highest honors in economics from St. Lawrence University and a J.D. degree from the Faculty of Law and Jurisprudence, State University of New York at Buffalo.
Vice President, Marketing & Commercial Operations
Scott Corning has more than 15 years of ophthalmic medical device and pharmaceutical marketing experience covering a range of ophthalmic surgical equipment, diagnostic devices and pharmaceuticals. Prior to joining Ocular Therapeutix in 2010, Mr. Corning held marketing management positions at Alcon in both the surgical and pharmaceutical divisions, and prior to that at Summit Technology, and Euroclear in Brussels. Mr. Corning earned a B.A. degree from Wesleyan University and received an M.S./M.A. degree in management and international relations from Boston University in Brussels, Belgium.
Vice President, Product Development
Art has more than 20 years of biomaterials, medical device and biotech experience in both public and private companies, with a strong record of developing technologies from bench top through commercialization. Prior to joining Ocular Therapeutix in 2011, Mr. Driscoll was Vice President of BioSurgery R&D for Covidien’s Surgical Solutions business and previously held senior management positions at Confluent Surgical and Boston Scientific. Mr. Driscoll has a B.S degree in industrial technology and was a candidate for an M.S. degree in plastics engineering from the University of Lowell.